HCPCS Level II drug code
J3405 — Injection, onasemnogene abeparvovec-brve, per treatment
In short
J3405 is the HCPCS Level II code for injection, onasemnogene abeparvovec-brve, per treatment. CMS assigns NDCs for Itvisma to it. The Medicare Part B payment limit is $2,729,937.922 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, onasemnogene abeparvovec-brve, per treatment
- Short descriptor
- Inj onase abepar-brve treat
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jul 1, 2026
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. CMS note: Added October 2026. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the units to build the claim line.
NDCs billed under J3405
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 1 NDC to J3405 for Itvisma. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Itvisma | 71894-0200-02 | Novartis Gene Therapies, Inc. | 3 | 1 |
J3405: common questions
- Is J3405 a CPT code?
- No. J3405 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J3405?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 1 NDC under J3405, for Itvisma. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J3405?
- $2,729,937.922 per per treatment, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.